Avid Bioservices Inc (CDMO)

[Amrsto1000]

Halozyme Therapeutics recently said it would focus on its Enhanze delivery technology after HALO-301 – its candidate pancreatic cancer drug – fell short in Phase III trials.

The San Diego biotech will close its oncology operations and reduce its headcount by approximately 55%, or approximately 160 positions. (Read Xconomy’s report here).

?

Image: iStock/lovelyday12

But the reorganization is not likely to have an impact on biopharma contract development and manufacturing organization (CDMO) Avid Bioservices, which counts Halozyme as its largest customer. Avid first entered into a manufacturing contract with the firm in 2004 and produces recombinant human hyaluronidase enzyme for both Halozyme and its partners